Impaired Humoral Response to Third Dose of BNT162b2 mRNA COVID-19 Vaccine Despite Detectable Spike Protein-specific T cells in Lung Transplant Recipients.
作者信息
Havlin Jan, Skotnicova Aneta, Dvorackova Eliska, Hubacek Petr, Svorcova Monika, Lastovicka Jan, Sediva Anna, Kalina Tomas, Lischke Robert
机构信息
Prague Lung Transplant Program, 3rd Department of Surgery, Charles University in Prague and Motol University Hospital, Prague, Czech Republic.
CLIP - Childhood Leukaemia Investigation Prague, Department of Pediatric Hematology and Oncology, Charles University in Prague and Motol University Hospital, Prague, Czech Republic.
出版信息
Transplantation. 2022 Mar 1;106(3):e183-e184. doi: 10.1097/TP.0000000000004021.
Abstract
摘要
相似文献
1
Impaired Humoral Response to Third Dose of BNT162b2 mRNA COVID-19 Vaccine Despite Detectable Spike Protein-specific T cells in Lung Transplant Recipients.
Transplantation. 2022 Mar 1;106(3):e183-e184. doi: 10.1097/TP.0000000000004021.
2
Antibody and T Cell Response to SARS-CoV-2 Messenger RNA BNT162b2 Vaccine in Kidney Transplant Recipients and Hemodialysis Patients.
J Am Soc Nephrol. 2021 Sep;32(9):2147-2152. doi: 10.1681/ASN.2021040480. Epub 2021 Jun 10.
3
Cellular and humoral immune responses after a third dose of SARS-CoV-2 mRNA vaccine in lung transplant recipients in Japan.
Vaccine. 2023 Jul 12;41(31):4534-4540. doi: 10.1016/j.vaccine.2023.06.011. Epub 2023 Jun 9.
4
Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients: A Randomized Clinical Trial.
JAMA Intern Med. 2022 Feb 1;182(2):165-171. doi: 10.1001/jamainternmed.2021.7372.
5
Serologic response to a third dose of an mRNA-based SARS-CoV-2 vaccine in lung transplant recipients.
Transpl Immunol. 2022 Jun;72:101599. doi: 10.1016/j.trim.2022.101599. Epub 2022 Apr 4.
6
Six-month humoral response to BNT162b2 mRNA COVID-19 vaccine in people with multiple sclerosis treated with natalizumab.
Neurol Sci. 2022 May;43(5):2947-2949. doi: 10.1007/s10072-022-05940-0. Epub 2022 Feb 16.
7
Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients.
J Am Soc Nephrol. 2021 Sep;32(9):2153-2158. doi: 10.1681/ASN.2021040490. Epub 2021 Jun 16.
8
Humoral response to heterologous prime-booster vaccination in heart transplant recipients aged 18-70 years primed with a viral vector SARS-CoV-2 vaccine.
Transpl Infect Dis. 2022 Dec;24(6):e13935. doi: 10.1111/tid.13935. Epub 2022 Aug 23.
9
Poor Antibody Response After Two Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine in Transplant Recipients.
Clin Infect Dis. 2022 Mar 23;74(6):1093-1096. doi: 10.1093/cid/ciab580.
10
The third dose of mRNA SARS-CoV-2 vaccines enhances the spike-specific antibody and memory B cell response in myelofibrosis patients.
Front Immunol. 2022 Sep 29;13:1017863. doi: 10.3389/fimmu.2022.1017863. eCollection 2022.
引用本文的文献
1
High Rate of Antibody Response to Multiple Doses of the COVID-19 Vaccine in Liver Transplant Recipients: Analysis of Predictive Factors.
Vaccines (Basel). 2025 Mar 26;13(4):352. doi: 10.3390/vaccines13040352.
2
Predominantly defective CD8 T cell immunity to SARS-CoV-2 mRNA vaccination in lung transplant recipients.
J Transl Med. 2023 Jun 8;21(1):374. doi: 10.1186/s12967-023-04234-z.
3
Immunogenicity, Safety, and Breakthrough Severe Acute Respiratory Syndrome Coronavirus 2 Infections After Coronavirus Disease 2019 Vaccination in Organ Transplant Recipients: A Prospective Multicenter Canadian Study.
Open Forum Infect Dis. 2023 Apr 13;10(5):ofad200. doi: 10.1093/ofid/ofad200. eCollection 2023 May.
4
Immunogenicity of a Third Dose of BNT162b2 Vaccine among Lung Transplant Recipients-A Prospective Cohort Study.
Vaccines (Basel). 2023 Apr 4;11(4):799. doi: 10.3390/vaccines11040799.
5
A new set-up of vanishing antibodies: A biennial follow-up of five different clients' humoral responses against SARS-CoV-2 after systemic vaccination in an oncology hospital in Poland.
Health Sci Rep. 2023 Mar 30;6(4):e1172. doi: 10.1002/hsr2.1172. eCollection 2023 Apr.
6
Efficacy of pre-exposure prophylaxis to prevent SARS-CoV-2 infection after lung transplantation: a two center cohort study during the omicron era.
Infection. 2023 Oct;51(5):1481-1489. doi: 10.1007/s15010-023-02018-7. Epub 2023 Mar 16.
7
Humoral and cellular immune response after severe acute respiratory syndrome coronavirus 2 messenger ribonucleic acid vaccination in heart transplant recipients: An observational study in France.
Front Med (Lausanne). 2022 Oct 26;9:1027708. doi: 10.3389/fmed.2022.1027708. eCollection 2022.
8
Efficacy and safety of the SARS-CoV-2 mRNA vaccine in lung transplant recipients: a possible trigger of rejection.
Gen Thorac Cardiovasc Surg. 2023 Apr;71(4):251-257. doi: 10.1007/s11748-022-01887-3. Epub 2022 Oct 26.
9
Immunogenicity and safety of the booster BNT162b2 vaccine in patients with axial spondyloarthritis treated with biological disease-modifying drugs.
Front Immunol. 2022 Sep 23;13:1010808. doi: 10.3389/fimmu.2022.1010808. eCollection 2022.
10
Outcome of lung transplant recipients infected with SARS-CoV-2/Omicron/B.1.1.529: a Nationwide German study.
Infection. 2023 Jun;51(3):749-757. doi: 10.1007/s15010-022-01914-8. Epub 2022 Sep 9.
Zotero 插件